CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 320 enrolled
Drug / intervention
DE-089 ophthalmic solution +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01189032
NCT01189032Phase 2Completed

Dose-Response Study of DE-089 Ophthalmic Solution in Patients With Dry Eye -Late Phase II Confirmatory Study-

Santen Pharmaceutical Co., Ltd.·interventional·Posted Aug 26, 2010·Updated Aug 13, 2014

In Brief

A Phase 2 clinical trial evaluating DE-089 ophthalmic solution and Placebo ophthalmic solution for Dry Eye. Completed, enrolled 320 participants across 1 site.

Detailed Summary

Dose response related to efficacy and safety of DE-089 ophthalmic solution are examined in patients with dry eye, using a multicenter, randomized, double-blind, parallel group comparison study, and the optimal concentration is determined.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 26, 2010
Primary CompletionJul 1, 2006
TodayJul 2, 2026
Posted 15.8 years ago

Interventions

DE-089 ophthalmic solutiondrug

DE-089 ophthalmic solutiondrug

Placebo ophthalmic solutiondrug